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Introduction: Diagnosing asthma in children remains a challenge because respiratory symptoms are not 
specific and vary over time. 
Aim: In a real-life observational study, we assessed the diagnostic accuracy of respiratory symptoms, 
objective tests, and two paediatric diagnostic algorithms proposed by GINA and NICE to diagnose asthma in 
school-aged children. 
Methods: We studied children aged 5-17 years referred consecutively for evaluation of suspected asthma 
to pulmonary outpatient clinics. Symptoms were assessed by parental questionnaire. The investigations 
included specific IgE measurement or skin prick tests, measurement of fractional exhaled nitric oxide, 
spirometry, body plethysmography, and bronchodilator reversibility. Asthma was diagnosed by paediatric 
pulmonologists based on all available data. We assessed diagnostic accuracy of symptoms, tests, and 
diagnostic algorithms by calculating sensitivity, specificity, positive and negative predictive values, and area 
under the curve (AUC). 
Results: Among 514 participants, 357(70%) were diagnosed with asthma. The combined sensitivity and 
specificity (sensitivity/specificity) was highest for any wheeze (0.75/0.65), dyspnoea (0.56/0.76), and 
wheeze triggered by colds (0.58/0.78) or by exercise (0.55/0.74). Of the diagnostic tests, the AUC was 
highest for specific total resistance (sRtot) (0.73) and lowest for the residual volume (RV) total lung capacity 
(TLC) ratio (0.56). The NICE algorithm had a sensitivity of 0.69 and specificity of 0.67, whereas the GINA 
algorithm had a sensitivity of 0.42 and specificity of 0.90. 
Conclusion: This study confirms the limited usefulness of single tests as well as existing algorithms for the 




Diagnosing asthma in children remains a challenge because respiratory symptoms such as wheeze and 
cough are not specific and vary over time, and asthma lacks an effective stand-alone diagnostic test. 
Clinically, physicians diagnose asthma based on a combination of symptoms, physical examination, and 
diagnostic tests [1-3]. Among available tests, spirometry and body plethysmography in combination with 
bronchodilator reversibility testing demonstrate reversible airway obstruction. Bronchial provocation tests 
measure bronchial hyper-responsiveness (BHR), fractional exhaled nitric oxide (FeNO) indicates airway 
inflammation, and allergy tests show underlying atopy. Diagnostic algorithms that combine these tests 
have recently been proposed by the National Institute for Health and Care Excellence (NICE) and the Global 
Initiative for Asthma (GINA) [1-3]. 
However, the accuracy of these diagnostic algorithms in school-aged children suspected for asthma is 
uncertain, which can lead to both under- and over treatment [3-5]. Systematic literature reviews done as 
part of the ongoing task force of the European Respiratory Society (ERS) on asthma diagnosis in children 
find few relevant studies [1-3]. A population-based assessment of the diagnostic accuracy of the algorithm 
proposed in the NICE guideline recommends against guideline implementation in the absence of better 
evidence [6]. In a recent assessment of diagnostic tests in 111 school-aged outpatients referred for 
suspected asthma, we found that accuracy was highest for reported triggers and severity of wheeze, FeNO, 
and BHR testing by methacholine or exercise [7]. But because the study of the NICE algorithm was based on 
the general population, and our study took place in a research setting, we lack data on the usefulness of 
these tests in everyday clinical situations. Body plethysmography in particular has also not been previously 
assessed. We therefore set out to assess the diagnostic accuracy of respiratory symptoms, diagnostic tests, 
and two paediatric diagnostic algorithms by GINA and NICE in school-aged children who were referred to 





Study population and study design 
We relied upon baseline measurements of the Swiss Paediatric Airway Cohort (SPAC), a prospective clinical 
cohort embedded in routine care [8]. This analysis used data from children aged 5-17 years invited to 
participate between July 2017 and June 2019. The primary care physicians wrote down the reason for 
referral in the referral letter. The 514 participants were consecutive referrals for symptoms suggestive of 
asthma: wheeze, cough (except wet cough without wheeze), exercise induced breathing problems, or 
dyspnoea. The children referred by their primary care physician for other reasons such as investigations of 
allergic rhinoconjunctivitis alone, or of sleep-disordered breathing, were not included. The study inclusion 
process is shown in Figure 1. 
Study procedures 
Participant families received a parental questionnaire either accompanying an invitation letter to attend 
the clinic or upon arrival at the outpatient clinic. At the visit, children underwent clinical evaluation, allergy 
testing (unless allergy test results were reported in the referral letter), measurement of FeNO, spirometry, 
body plethysmography, and bronchodilator reversibility testing. When indicated, children also underwent 
bronchial hyperresponsiveness testing by methacholine, exercise, or mannitol either during the same visit 
or at a follow-up visit within three months. Ethical approval was obtained from the Bernese ethics 
committee (KEB 2016-02176) and all participating parents and adolescents aged 14 years or older gave 
written informed consent. 
 
Clinical asthma diagnosis 
The clinical diagnosis of definite asthma, probable asthma, or other disease was the one noted by the 
experienced paediatric pulmonologist in the letter sent back to the referring primary care physician. The 
diagnosis was based on medical history, clinical examination, and all test results, and was regarded as the 
reference standard. The results of the parental questionnaire were not available to the paediatric 
pulmonologists when making the diagnosis. When the diagnosis was unclear (that is, was described as 
 
probable asthma) and a follow-up visit took place within 3 months, we used the clinical diagnosis from the 
follow-up visit. 
 
Respiratory symptoms and diagnostic tests 
The parental questionnaire included key questions about lower respiratory symptoms from the 
International Study of Asthma and Allergies in Childhood (ISAAC) and further detailed questions from the 
Leicester respiratory cohort questionnaires [9, 10]. Dyspnoea was assessed using the question: “Hatte Ihr 
Kind in den letzten 12 Monaten Atemnot?” (German) meaning “In the past 12 months did your child have 
episodes of breathlessness?” in English. All diagnostic tests were performed according to published 
guidelines [11, 12]. Children were asked to withhold short-acting beta2-agonists for 8 hours, inhaled 
corticosteroids, leukotriene antagonists, and long acting beta2-agonists for 24 hours, and antihistamines 
and sodium cromoglycate for >72 hours before the visit. 
Skin prick tests and specific IgE measurements were used to measure atopy. Skin prick tests were done 
using histamine, saline and birch, grass, mugwort, alternaria, cat, and house dust mites (D. pteronyssinus 
and farinae) [13]. A wheal size of ≥3 mm was considered positive in case the positive control (histamine) 
had a wheal size of ≥3 mm and the negative control (saline) had a wheal size of <3mm. Specific IgE levels 
for birch, grass, mugwort, alternaria, cat, house dust mites were measured in serum samples using the 
fluorescence enzyme immunoassay/immunocap (Thermo Fisher Scientific, Uppsala, Sweden). IgE levels 
were considered positive at the detection threshold (≥0.35 kU/l). 
Fractional exhaled nitric oxide (FeNO) was measured in doublets before spirometry using the portable 
multi-gas analyser (NIOX MINO®, Aerocrine, Sweden) in St. Gallen and the CLD 88sp (Ecomedics) in Bern, 
Basel, Aarau, Zurich, and Luzern in accordance with published guidelines [12]. These devices show good 
agreement [14]. 
Spirometry and body plethysmography were performed using American Thoracic Society (ATS) criteria for 
paediatric lung function testing and a Jaeger masterscope (Erich Jaeger GmbH, Würzburg, Germany) using 
JLAB software (version 4.34) (Basel and St. Gallen) or MasterScreen Pneumo spirometer using Sentrysuite 
 
software (Bern, Zurich, Aarau, and Lucerne). Spirometry was done in triplicate by experienced lung function 
technicians who performed quality control during the measurement and recorded the best measurement. 
The flow-volume curve was checked by the responsible paediatric pulmonologist. Results of the spirometry 
(forced expiratory volume in 1 second (FEV1) and forced expiratory flow (FEF) at 50% of the forced vital 
capacity (FVC)) are expressed as z-scores based on GLI-2012 reference standards [15] and as proportion 
(FEV1/FVC). The results of body plethysmography are expressed as kPa∙s for the specific effective airway 
resistance (sReff) and specific total airway resistance (sRtot) and as proportion (residual volume/total lung 
capacity). 
Bronchodilator reversibility tests were performed if FEV1 was ≤90%, FEF75 ≤67%, FEF50 ≤67%, or FEF25 
≤67% (Lucerne, Zurich and Aarau), if SReff >180% or FEF50 <80% (Bern), or in all patients (St. Gallen and 
Basel). All centres gave salbutamol 400 g (Ventolin® pMDI via spacer) to assess bronchodilator 
reversibility. Spirometry was repeated in duplicate after 10 (Lucerne and Basel), 15 (St. Gallen, Aarau, and 
Bern) or 20 minutes (Zurich). Bronchodilator reversibility was calculated by the following equation: (post-
bronchodilator FEV1–pre-bronchodilator FEV1)x100/pre-bronchodilator FEV1. 
 
Statistical analysis 
We calculated sensitivity, specificity, positive predictive value and negative predictive value, Youden’s Index 
(sensitivity + specificity – 1), area under the curve (AUC) and 95% confidence intervals (CI) for the reported 
symptoms and diagnostic tests to diagnose asthma. The cut-off with the best diagnostic accuracy was the 
value with the highest Youden’s index. We assessed the diagnostic accuracy of tests if they were performed 
in at least 70% of the children. To assess the diagnostic accuracy of bronchodilator reversibility we did a 
subanalysis in children with obstructive lung function (FEV1/FVC <80%) [1, 16]. We performed an initial 
sensitivity analysis in which we classified children with “probable asthma” as having “no asthma”. We did a 
second sensitivity analysis using only steroid naïve children. We applied the asthma diagnosis algorithms by 
GINA and NICE to assess how they would have performed in a clinical setting and calculated sensitivity, 
 
specificity, positive predictive value, and negative predictive value. We used STATA software (version 15; 





Characteristics of the study population 
Of the 514 children fulfilling the inclusion criteria, 294 (57%) were male and the median age was 9 years. 
Nearly two-thirds of the referred children reported wheeze, and over half wheeze and/or cough. Asthma 
had been diagnosed in 356 (69%) of the participants. Table 1 presents the full characteristics of the 
participants. Exercise limitation (56 children, 11%) and cough (71 children, 14%), both not due to asthma, 
were frequent other diagnoses (table S1). 
Table 1. Characteristics of the study participants (N=514) 
 Total 
n (%) 
     Age, median [IQR] 9  [7-12] 
     Sex, male 294 (57) 
     BMI, median z-score [IQR] 0.3 [-0.4-1.1] 
Respiratory symptoms in the last 12 months   
     Any wheeze 317   (62) 
     More than 3 attacks of wheeze 170   (33) 
     Wheeze with colds 230 (45) 
     Exercise-induced wheeze 232    (45) 
     Wheeze triggered by pollen 127 (25) 
     Wheeze triggered by house dust 81 (16) 
     Wheeze triggered by pets 64 (12) 
     Awakening due to wheeze 182 (35) 
     Cough longer than 4 weeks 214 (42) 
     Night cough 271 (53) 
     Cough more than others 281 (55) 
     Dyspnoea 230 (45) 
Inhalation medication in the last 12 months   
     Any 395 (77) 
     Short-acting B2-agonist, alone 152 (30) 
     ICS +/- Short-acting B2-agonist 114 (22) 
     ICS + Long-acting B2-agonist 129 (25) 




Diagnostic accuracy of respiratory symptoms to diagnose asthma 
Any reported wheeze in the past 12 months had the highest sensitivity (74%) and Youden’s Index (0.39) for 
asthma (table 2). Specificity was highest for frequent attacks (>3/year) (84%), awakening due to wheeze 
(82%), and wheeze triggered by pollen (92%), house dust (97%), or pets (97%). Youden’s Index was also 
relatively high for wheeze triggered by colds (0.36), exercise (0.30), and dyspnoea (0.31). 
 























in the past 12 months 
         
Any wheeze 262 55 90 100 74 (70-79) 65 (56-72) 83 (78-87) 53 (45-60) 0.39 
> 3 attacks of wheeze 145 25 200 129 42 (37-47) 84 (77-89) 85 (79-90) 39 (34-45) 0.26 
Wheeze with colds 196 34 141 120 58 (53-63) 78 (71-84) 85 (80-90) 46 (40-52) 0.36 
Exercise-induced wheeze 192 40 154 115 55 (50-61) 74 (67-81) 83 (77-87) 43 (37-49) 0.30 
Wheeze triggered by          
     Pollen 115 12 227 145 34 (29-39) 92 (87-96) 91 (84-95) 39 (34-44) 0.26 
     House dust 76 5 259 150 23 (18-28) 97 (93-99) 94 (86-98) 37 (32-42) 0.19 
     Pets 59 5 274 152 18 (14-22) 97 (93-99) 92 (83-97) 36 (31-40) 0.15 
Awakening due to wheeze 155 27 191 127 45 (39-50) 82 (76-88) 85 (79-90) 40 (35-46) 0.27 
Cough > 4 weeks 140 74 209 81 40 (35-45) 52 (44-60) 65 (59-72) 28 (23-33) -0.08 
Night cough 189 82 153 74 55 (50-61) 47 (39-56) 70 (64-75) 33 (27-39) 0.03 
Cough more than others 200 81 146 70 58 (52-63) 46 (38-55) 71 (65-76) 32 (26-39) 0.04 
Dyspnoea 192 38 154 116 55 (50-61) 75 (68-82) 83 (78-88) 43 (37-49) 0.31 
A+S+: children with asthma diagnosis and reported symptom, A-S+: children without asthma diagnosis but with 
symptom, A+S-: children with asthma diagnosis but without symptom, A-S-: children without asthma and without 
symptom, Sens: sensitivity, Spec: specificity, PPV: positive predictive value, NPV: negative predictive value YI: 




Diagnostic accuracy of tests to diagnose asthma 
The tests done in each centre and their results are shown in tables S2 and S3. Allergy tests were performed 
in 467 (91%) of the 514 children. FeNO was performed in 501 (97%), spirometry in all 514, body 
plethysmography in 432 (84%), and bronchodilator reversibility in 381 children (74%). Of these performed 
measurements, we excluded 63, 19, 45, and 15, respectively, because of poor quality. The accuracy of 
bronchial hyperresponsiveness testing was not assessed, because it was only performed in 210 (41%) 
children. 
The cut-off values with the best diagnostic accuracy were ≥1 positive test for the allergy test, ≥23ppb for 
FeNO, ≤-0.7 z score for FEV1, <84% for FEV1/FVC, ≤-0.3 z score for FEF50, ≥0.9 kPa∙s for sReff, ≥1.1 kPa∙s for 
sRtot, ≥25% for RV/TLC, and ≥7% increase in FEV1 for the bronchodilator reversibility test (table 3). The 
diagnostic accuracy (area under the curve) was highest for sRtot (0.74), allergy tests (0.70), FEF50 (0.69), 
and FeNO (0.68). The accuracy was lowest for RV/TLC (0.56) and the bronchodilator reversibility test (0.60). 
However, bronchodilator reversibility had the highest accuracy (0.75) when we analysed only data from 


























Clinical tests           
Allergy test1          0.70 
     ≥1 positive test* 260 52 81 74 76 (71-81) 59 (50-67) 83 (79-87) 48 (40-56) 0.35  
     ≥2 positive tests 199 34 142 92 58 (53-64) 73 (64-81) 85 (80-90) 39 (33-46) 0.31  
FeNO          0.68 
     ≥20ppb 157 31 147 103 52 (46-57) 77 (69-84) 84 (77-89) 41 (35-48) 0.29  
     ≥21ppb 153 27 151 107 50 (45-56) 80 (72-86) 85 (79-90) 41 (35-48) 0.30  
     ≥23ppb* 145 18 159 116 48 (42-53) 87 (80-92) 89 (83-93) 42 (36-48) 0.34  
     ≥25ppb 139 16 165 118 46 (40-52) 88 (81-93) 90 (84-94) 42 (36-48) 0.34  
Spirometry           
  FEV1          0.66 
     ≤-0.7 z-score* 148 30 195 121 43 (38-49) 80 (73-86) 83 (77-88) 38 (33-44) 0.23  
     ≤-1.0 z-score 109 23 234 128 32 (27-37) 85 (78-90) 83 (75-89) 35 (30-41) 0.17  
  FEV1/FVC          0.65 
     <80% 120 15 216 128 36 (31-41) 90 (83-94) 89 (82-94) 37 (32-43) 0.25  
     <84%* 174 33 162 110 52 (46-57) 77 (69-84) 84 (78-89) 40 (35-47) 0.29  
     <90% 245 84 91 59 73 (68-78) 41 (33-50) 74 (69-79) 39 (31-48) 0.14  
FEF50          0.69 
     ≤-0.3 z-score* 171 31 122 93 58 (52-64) 75 (66-82) 85 (79-89) 43 (37-50) 0.33  
     ≤-1.0 z-score 96 13 197 111 33 (27-38) 90 (83-94) 88 (80-93) 36 (31-42) 0.22  
Bodyplethysm.           
  sReff2          0.66 
     ≥0.9 kPa∙s/l* 118 25 114 76 51 (44-57) 75 (66-83) 83 (75-88) 40 (33-47) 0.26  
     ≥1.0 kPa∙s/l 96 18 136 83 41 (35-48) 82 (73-89) 84 (76-90) 38 (31-45) 0.24  
  sRtot3          0.74 
     ≥1.0 kPa∙s/l 35 11 4 6 90 (76-97) 35 (14-62) 76 (61-87) 60 (26-88) 0.25  
     ≥1.1 kPa∙s/l * 32 7 7 10 82 (66-92) 59 (33-82) 82 (66-92) 59 (33-82) 0.41  
  RV/TLC          0.56 
     ≥25%* 204 80 61 36 77 (71-82) 31 (23-40) 72 (66-77) 37 (28-48) 0.08  
Bronchodilator rev.          0.60 
  FEV1           
     ≥7% increase* 188 43 86 49 69 (63-74) 53 (43-64) 81 (76-86) 36 (28-45) 0.22  
     ≥10% increase 160 37 114 55 58 (52-64) 60 (49-70) 81 (75-86) 33 (26-40) 0.18  
     ≥12% increase 145 34 129 58 53 (47-59) 63 (52-73) 81 (74-86) 31 (24-38) 0.16  
Bronchodilator rev. 
if FEV1/FVC <80%4 
         0.75 
     ≥7% increase* 89 4 23 9 79 (71-87) 69 (39-91) 96 (89-99) 28 (14-47) 0.49  
     ≥10% increase 73 3 39 10 65 (56-74) 77 (46-95) 96 (89-99) 20 (10-34) 0.42  
     ≥12% increase 65 2 47 11 58 (48-67) 85 (55-98) 97 (90-99) 19 (10-31) 0.43  
A+T+: children with asthma diagnosis and positive test result, A-T+: children without asthma diagnosis but positive 
test result, A+T-: children with asthma diagnosis but negative test result, A-T-: children without asthma and negative 
test result, Sens: sensitivity, Spec: specificity, PPV: positive predictive value, NPV: negative predictive value, YI: 
Youden’s-Index: Sensitivity + Specificity -1, AUC: area under the curve, FeNO: fractional exhaled nitric oxide, ppb: parts 
per billion, FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, FEF50: forced expiratory flow at 50% 
of FVC, sReff: specific effective airway resistance, sRtot: specific total airway resistance, RV: residual volume, TLC: total 
lung capacity, Bronchodilator rev.: bronchodilator reversibility 
Displayed cut-offs chosen based on proposed cut-offs from previous publications 
*Cut-off with maximum combined sensitivity and specificity (highest Youden’s-Index) 
1 Number allergens for which the skin prick test is positive: wheal size ≥3 or the specific IgE test was positive: ≥0.35 
kU/l. 
2 Reported by 4 centres 
3
 Reported by 2 centres 
4




In the sensitivity analysis, where we classified children diagnosed with “probable asthma” as having “no 
asthma”, the cut-offs with highest combined sensitivity and specificity changed only slightly for FEV1 (from 
≤-0.7 z score to ≤-0.2 z score) and FEF50 (from ≤-0.3 z score to ≤-0.5 z score). The diagnostic accuracy (area 
under the curve) remained highest for FEF50 (0.73) and FeNO (0.70) and increased for FEV1/FVC (from 0.65 
to 0.72), and sReff (from 0.66 to 0.68). The accuracy remained lowest for RV/TLC (0.53) and the 
bronchodilator reversibility test (0.60) (table s4).  
In the second sensitivity analysis, which included only ICS naïve children, asthma was diagnosed in 156 
(58%) of the 271 children (table s5). The cut-offs with highest combined sensitivity and specificity changed 
for FeNO from ≤23 ppb to ≤28 ppb, FEV1/FVC from 84% to 86%, sRtot from 1.1 kPa∙s to 1.5 kPa∙s, and 
RV/TLC from ≥25% to ≥35%. The diagnostic accuracy remained highest for sRtot (0.77), the allergy test 
(0.71), FEF50 (0.70), and FeNO (0.71) as in the main analysis. The accuracy was still lowest for RV/TLC (0.51) 
and bronchodilator reversibility (0.56) (table S6). 
 
Diagnostic accuracy of algorithms to diagnose asthma 
We applied the GINA diagnostic algorithm to the 514 children suspected for asthma. We were able to pass 
91 children through the proposed pathway to the step “treat for asthma” (figure 3). Of these, 81 (positive 
predictive value [PPV] 89%) were diagnosed with asthma by our paediatric pulmonologist. Of the 210 
children we could pass through the algorithm to the step “consider alternative diagnosis,” 111 were 
diagnosed with asthma, and 99 (negative predictive value [NPV] 47%) were not. The sensitivity of the 
algorithm was 42% and the specificity was 90%. In 168 children, the GINA algorithm would have been 
inconclusive because they ended at the step “repeat on another occasion or arrange other tests”; the 
paediatric pulmonologists in our study diagnosed 132 of these children with asthma. 
We also applied the NICE diagnostic algorithm to the 514 children suspected for asthma. We were only able 
to pass 38 children through to the step “diagnose asthma” (figure S2). Of these 38 children, 35 (PPV 92%) 
 
were diagnosed with asthma by the paediatric pulmonologists. Of the 22 children whom we could pass 
through to the step “refer for specialist assessment,” 18 were diagnosed with asthma and 6 (NPV 27%) 
were not. The sensitivity was thus 69% and the specificity 67%. However, 362 (83%) children were stuck at 




This study found that the commonly used tests, alone or in combination as suggested by GINA or NICE, are 
not very helpful in diagnosing asthma in routine, clinical care. We found that the combined sensitivity and 
specificity to diagnose asthma in our study was highest for any wheeze (sensitivity/specificity, 74/65) and 
the diagnostic accuracy (area under the curve) was highest for sRtot (0.74), a positive allergy test (0.70), 
FEF50 (0.69), FeNO (0.68), and the bronchodilator reversibility test in children with FEV1/FVC <80% (0.75), 
and lowest for RV/TLC (0.56). The NICE algorithm relied too much on 2 weeks’ PEF monitoring, which 
should have been done in 83% of children according to the algorithm. This is not practical for an outpatient 
setting. The GINA paediatric diagnostic algorithm was specific (90%), but not sensitive (42%).  
This is the first study of the diagnostic accuracy of body plethysmography and the largest study to 
investigate the usefulness of respiratory symptoms, diagnostic tests, and algorithms to diagnose asthma in 
routine care. A few studies have assessed the accuracy of symptoms and tests in school-aged children 
consecutively referred for evaluation of possible asthma [7, 17-19]. They all found that reported wheeze 
was sensitive (ranging 75-86%) but not specific (64-73%), and that frequent wheeze and awakening due to 
dyspnoea were specific (84-90%) but not sensitive (33-54%), which is in line with our findings. Another way 
to phrase this would be that, if for example frequent wheeze is mentioned in the history, a physician is 
highly likely to make an asthma diagnosis. In our previous study in a different clinical population, the 
combined sensitivities and specificities were highest for the same symptoms. In that study, wheeze with 
colds and dyspnoea also scored high [7]. Also in that study and as reported by Woo et al., we confirmed 
that a positive skin prick test was sensitive (68-90%) but not specific (32-40%) [20]. The area under the 
 
curve (AUC) for FeNO in our study (0.68) was lower than in our previous study (0.79), and in a Korean study 
by Eom et al. (0.80) [7, 21]. In steroid naïve children, we expected the diagnostic accuracy for FeNO to be 
higher, because ICS treatment reduces FeNO levels. This was not the case, which could have two reasons: 
(1) the ICS naïve children were less severely affected and episodes were mostly triggered by colds. FeNO 
levels are lower in mildly affected children without allergic triggers, reducing the diagnostic accuracy in 
treated children. (2) The question on ICS use was imprecise. We asked about use of ICS in the last 12 
months. This includes current use of ICS but did not allow for an analysis of current use of ICS separately. 
FEV1/FVC had low diagnostic accuracy in all studies. FEF25-75 (0.81) and FEF50 (0.69) seem to perform 
better. Differences in the AUC between the Korean and our study could be due to their exclusion of the 
children with unclear asthma. A study by Korten et al. found that adding sRtot and RV/TLC measured during 
bodyplethysmography to spirometry measures improved the agreement with the asthma control test in a 
cohort of 145 asthmatic children from Germany [22]. In our study, sRtot had the highest AUC to diagnose 
asthma. However, if we want to assess its value in addition to spirometry, we would need to perform a 
prospective study.  
The NICE algorithm has previously been tested using data from the Manchester Asthma and Allergy Study, 
a population-based cohort of 1184 children aged 13-16 years, of which 89 were symptomatic but not 
regularly inhaling corticosteroids [6]. That study found that less stringent cutoff values had higher 
sensitivity and specificity than those proposed in the algorithm. However, the Manchester study compared 
children with asthma defined by parent reports of wheeze and asthma treatment in the past 12 months 
plus a doctor diagnosis of asthma ever in life, to healthy children, excluding from the analysis all those with 
possible asthma. In clinical practice, we want to distinguish children with asthma from those with 
respiratory symptoms due to other causes, not from healthy children.  In our clinical population, only 38 
children out of 514 could be diagnosed with asthma based on the NICE algorithm (FEV1/FVC <70% and 
bronchodilator responsibility of ≥12%) in our clinical population. Nearly all (83%) would have needed an 
additional two weeks’ peak expiratory flow (PEF) monitoring followed by a second visit to the outpatient 
clinic (Figure S2). In addition to the fact that this test is not used in most countries, it would also not be 
 
practical for a busy outpatient clinic. In low income settings, however, PEF monitoring might be the only 
test available and its value should be studied further. We also found less stringent cut-off values of <84% 
for FEV1/FVC, ≥7% for bronchodilator reversibility, and ≥23ppb for FeNO to have higher sensitivity and 
specificity than the values proposed by the NICE algorithm: <70% for FEV1/FVC, ≥12% for bronchodilator 
reversibility, and ≥35ppb for FeNO. The accuracy of the GINA diagnostic algorithm has not previously been 
studied. At 90% its specificity is relatively high, but this would still lead to 10% overdiagnosis of asthma. The 
sensitivity was only 42%, which means that the GINA algorithm would identify less than half of the children 
diagnosed by paediatric pulmonologists.  
 
A main weakness of this study, which is unavoidable, is that the reference standard for asthma diagnosis, 
the physician’s diagnosis, drew upon patient history and diagnostic test results, of which we were assessing 
the accuracy. So, while we found that wheeze triggered by pollen is very specific for asthma (specificity 
92%), we could phrase this finding also the other way around, i.e. that physicians are unlikely to give 
another diagnosis than asthma if parents report wheeze triggered by pollen. However, given the lack of a 
stand-alone diagnostic test for asthma, the physician’s diagnosis based on a full patient history, physical 
examination, and diagnostic test results is closest to the true diagnosis [1, 23, 24]. The multicentre study 
adds heterogeneity in the tests and diagnoses, but it increases generalisability of the findings. Finally, some 
tests were not done in all children. This could have introduced a selection bias because the children who 
were tested could differ from those who were not. However, the percentage not tested was low, limiting 
the potential bias because we only evaluated tests done in more than 70% of the children. 
The main strength of our study is that it was embedded in routine care and included the whole spectrum of 
children newly referred with suspected asthma to paediatric respiratory outpatient clinics. We could also 
restrict the analysis to a steroid-naïve population, with comparable findings. Finally, we could assess the 
diagnostic accuracy of body plethysmography, which has not been done before and might be a useful test 
to add to spirometry for the diagnosis of asthma. 
 
 
Our findings highlight the need for better diagnostic algorithms combining respiratory symptoms and 
objective tests to diagnose asthma. The algorithms proposed by GINA and NICE guidelines do not seem to 
be very practical for an outpatient setting, and did not agree well with pulmonologists’ diagnoses. Our 
findings confirm that the cut-offs used in the NICE algorithm are not appropriate for children. If we require 
a low FEV1/FVC ratio (less than 90% predicted) or significant bronchodilator responsiveness (>12%) to 
diagnose asthma, we are likely to underdiagnose asthma in children - particularly those who are already on 
ICS. This highlights the need to base diagnostic algorithms on clinical studies of appropriate age groups to 
generate evidence for threshold values of different tests relevant to the diagnosis of asthma in those 
groups—children in particular. The next step in research should take a systematic approach to assessing 
respiratory symptoms, allergy, FeNO, spirometry, body plethysmography, and bronchodilator reversibility 
tests in all children to develop an accurate diagnostic algorithm combining these tests.  
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Figure 1 Inclusion of study participants 
 
Figure 2 Receiver operating characteristics (ROC) curve of clinical tests to diagnose asthma.  
Test      Unit 
Allergy test npos     increase of 1 positive skin prick or specific IgE test 
FeNO      increase of 1 parts per billion (ppb) 
FEV1       increase of 0.1 z-score 
FEV1/FVC      increase of 1% 
FEF50      increase of 0.1 z-score 
sReff      decrease of 0.01 kPa∙s 
sRtot      decrease of 0.01 kPa∙s 
RV/TLC      increase of 5% 
Bronchodilator reversibility (BDR), FEV1  increase of 1% in FEV1  
 
Figure 3 Diagnostic accuracy of the algorithm proposed by the GINA guideline 
Numbers in black: number of patients at this step. Numbers in red: number of patients with doctor diagnosed asthma 
at this step. Algorithm +: treat for asthma. Algorithm -: consider alternative diagnosis. FEV1: forced expiratory volume 
in 1 second. FVC: forced vital capacity. BDR: bronchodilator reversibility 
*168 patients would need to repeat the spirometry and bronchodilator reversibility measurement or bronchial 
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Table S1. Diagnoses in children with suspected asthma after visiting the clinic* N=514 
 Diagnoses 
n (%) 
Definite diagnoses   
     Asthma 259 (50) 
     Cough not due to asthma1 71 (14) 
     Exercise limitation not due to asthma2 56 (11) 
     Allergic rhinoconjunctivitis 11 (2) 
     Non-CF bronchiectasis 1 (<1) 
Probable diagnoses   
     Asthma 97 (19) 
     Exercise limitation not due to asthma
2
 19 (4) 
*Diagnosis at the first visit at a follow up visit within 3 months if the diagnosis was unclear 
1 Recurrent colds, post infectious cough, habitual cough, etc. 
2 









Table S2. Proportion of patients who performed diagnostic tests* per centre N=514 

























Any allergy test1 60 (100) 182 (93) 74 (89) 55 (73) 15 (100) 81 (95) 467 (91) 
FeNO 60 (100) 185 (94) 81 (98) 75 (100) 15 (100) 85 (100) 501 (97) 
Spirometry  60 (100) 196 (100) 83 (100) 75 (100) 15 (100) 85 (100) 514 (100) 
Body plethysmography 59 (98) 171 (87) 52 (63) 61 (81) 10 (67) 79 (93) 432 (84) 
Bronchodilator reversibility  29 (48) 145 (74) 61 (73) 68 (91) 15 (100) 63 (74) 381 (74) 
Any bronchial provocation test 13 (22) 86 (44) 23 (28) 23 (31) 7 (47) 58 (68) 210 (41) 
     Methacholine 7 (12) 71 (36) 2 (2) 1 (1) - 48 (56) 129 (25) 
     Exercise 7 (12) 18 (9) 21 (25) 22 (29) 5 (33) 12 (14) 85 (17) 
     Mannitol - - - - 3 (20) - 3 (1) 
*At the first visit or at a follow up visit within 3 months 






Table S3. Diagnostic test results in patients with and without asthma N=514 




Definite asthma  
N=259 
median (IQR) 
 Probable asthma 
N=97 
median (IQR) 
 Other diagnosis 
N=158 
median (IQR) 
         
Any allergy test, n(%) 248 (96)  93 (95)  124 (79) 
     ≥1 positive test n(%) 201 (74)  59 (61)  52 (36) 
     Number of positive tests1 2 (1-3)  1 (0-3)  0 (0-2) 
         
FeNO, n(%) 227 (88)  77 (80)  134 (84) 
     Parts per billion 25 (12-50)  14 (8-28)  11 (7-18) 
         
Spirometry, n(%) 253 (98)  90 (93)  152 (96) 
     FEV1, z-scores -0.5 (-1.4-0.1)  -0.2 (-1.0-0.5)  0.1 (-0.6-0.8) 
     FEV1/FVC 82 (76-88)  90 (84-95)  88 (84-93) 
     FEF50, z-score -0.8 (-1.4--0.1)  0.1 (-0.7-0.9)  0.2 (-0.4-0.9) 
         
Bodyplethysmography, n(%) 197 (76)  73 (75)  117 (74) 
     sReff, kPa∙s2 1.0 (0.8-1.3)  0.8 (0.7-0.9)  0.8 (0.6-0.9) 
     sRtot, kPa∙s3 1.3 (1.1-1.8)  1.4 (1.3-1.5)  1.1 (1.0-1.3) 
     RV/TLC 30 (25-36)  30 (26-36)  29 (24-34) 
         
Bronchodilator reversibility, n(%) 215 (83)  59 (60)  92 (59) 
     Increase in FEV1 in %  13 (6-25)  10 (1-26)  6 (2-18) 
1Defined as wheal size ≥3mm for mites, cat, grass, birch, mugwort and alternaria skin prick test and as ≥0.35kU/L for 
specific IgE test 
2 Reported by 4 centres 




Table S4. Diagnostic accuracy of diagnostic tests to diagnose asthma N=514 (sensitivity analysis: where 






















Clinical tests           
Allergy test1          0.67 
     ≥1 positive test* 201 111 47 108 81 (76-86) 49 (43-56) 64 (59-70) 70 (62-77) 0.30  
     ≥2 positive tests 154 79 94 140 62 (56-68) 64 (57-70) 66 (60-72) 60 (53-66) 0.26  
FeNO          0.70 
     ≥20ppb 130 58 97 153 58 (51-64) 73 (66-78) 69 (62-76) 61 (55-67) 0.30  
     ≥21ppb 127 53 100 158 56 (49-63) 75 (68-81) 71 (63-77) 61 (55-67) 0.31  
     ≥23ppb* 119 44 108 167 52 (46-59) 79 (73-84) 73 (66-80) 61 (55-67) 0.32  
     ≥25ppb 114 41 113 170 50 (44-57) 81 (75-86) 74 (66-80) 60 (54-66) 0.31  
Spirometry           
  FEV1          0.64 
     ≤-0.2 z-score* 159 102 94 139 63 (57-69) 58 (51-64) 61 (55-67) 60 (53-66) 0.21  
     ≤-0.7 z-score 111 67 142 174 44 (38-50) 72 (66-78) 62 (55-69) 55 (49-61) 0.16  
     ≤-1.0 z-score 87 45 166 196 34 (29-41) 81 (76-86) 66 (57-74) 54 (49-59) 0.16  
  FEV1/FVC          0.72 
     <80% 107 28 141 203 43 (37-50) 88 (83-92) 79 (71-86) 59 (54-64) 0.31  
     <84%* 153 54 95 177 62 (55-68) 77 (71-82) 74 (67-80) 65 (59-71) 0.38  
     <90% 202 127 46 104 81 (76-86) 45 (38-52) 61 (56-67) 69 (61-77) 0.26  
FEF50          0.73 
     ≤-0.5 z-score* 131 46 87 155 60 (53-67) 77 (71-83) 74 (67-80) 64 (58-70) 0.37  
     ≤-1.0 z-score 83 27 135 174 38 (32-45) 87 (81-91) 75 (66-83) 56 (51-62) 0.25  
Bodyplethysm.           
  sReff          0.68 
     ≥0.9 kPa∙s* 98 45 68 122 59 (51-67) 73 (66-80) 69 (60-76) 64 (57-71) 0.32  
     ≥1.0 kPa∙s 81 33 85 134 49 (41-57) 80 (73-86) 71 (62-79) 61 (54-68) 0.29  
  sRtot          0.64 
     ≥1.0 kPa∙s 28 18 4 6 88 (71-96) 25 (10-47) 61 (45-75) 60 (26-88) 0.13  
     ≥1.1 kPa∙s * 25 14 7 10 78 (60-91) 42 (22-63) 64 (47-79) 59 (33-82) 0.20  
  RV/TLC          0.53 
     ≥25%* 150 134 45 52 77 (70-83) 28 (22-35) 53 (47-59) 54 (43-64) 0.05  
Bronchodilator rev.          0.60 
  FEV1           
     ≥7% increase* 156 75 59 76 73 (66-78) 50 (42-59) 68 (61-74) 56 (47-65) 0.23  
     ≥10% increase 131 66 84 85 61 (54-67) 56 (48-64) 66 (59-73) 50 (43-58) 0.17  
     ≥12% increase 117 62 98 89 54 (48-61) 59 (51-67) 65 (58-72) 48 (40-55) 0.13  
Bronchodilator rev. if 
FEV1/FVC <80%4 
         0.70 
     ≥7% increase* 83 10 18 14 82 (73-89) 58 (37-78) 89 (81-95) 44 (26-62) 0.41  
     ≥10% increase 68 8 33 16 67 (57-76) 67 (45-84) 89 (80-95) 33 (20-48) 0.34  
     ≥12% increase 60 7 41 17 59 (49-69) 71 (49-87) 90 (80-96) 29 (18-43) 0.30  
A+T+: children with asthma diagnosis and positive test result, A-T+: children without asthma diagnosis but positive test 
result, A+T-: children with asthma diagnosis but negative test result, A-T-: children without asthma and negative test 
result, Sens: sensitivity, Spec: specificity, PPV: positive predictive value, NPV: negative predictive value, YI : Youden’s-Index: 
Sensitivity + Specificity -1, AUC: area under the curve, FeNO: fractional exhaled nitric oxide, ppb: parts per billion, FEV1: 
forced expiratory volume in 1 second, FVC: forced vital capacity, FEF50: forced expiratory flow at 50% of FVC, sReff: 
specific effective airway resistance, sRtot: specific total airway resistance, RV: residual volume, TLC: total lung capacity, 
Bronchodilator rev.: bronchodilator reversibility 
Displayed cut-offs chosen based on proposed cut-offs from previous publications 
 
*Cut-off with maximum combined sensitivity and specificity (highest Youden’s-Index) 
1 Number allergens for which the skin prick test is positive: wheal size ≥3 or the specific IgE test was positive: ≥0.35 kU/l.  
2
 Reported by 4 centres 
3 Reported by 2 centres 





Figure S1 Receiver operating characteristics (ROC) curve of clinical tests to diagnose asthma. (Sensitivity 
analysis: “asthma” is defined as definite asthma and “not asthma” is defined as probable asthma or other 
diagnosis) 
* Cut-off with maximum combined sensitivity and specificity 
Test      Unit 
Allergy test npos     increase of 1 positive skin prick or specific IgE test 
FeNO      increase of 1 parts per billion (ppb) 
FEV1       increase of 0.1 z-score 
FEV1/FVC      increase of 1% 
FEF50      increase of 0.1 z-score 
sReff      decrease of 0.01 kPa∙s 
sRtot      decrease of 0.01 kPa∙s 
RV/TLC      increase of 5% 
Bronchodilator reversibility (BDR), FEV1  increase of 1% in FEV1 
  
 
Table S5. Diagnostic test results in steroid naive patients with and without asthma N=271 




Definite asthma  
N=108 
median (IQR) 
 Probable asthma 
N=48 
median (IQR) 
 Other diagnosis 
N=115 
median (IQR) 
         
Any allergy test, n(%) 101 (94)  46 (96)  86 (75) 
     ≥1 positive test n(%) 87 (81)  31 (65)  39 (34) 
     Number of positive tests1 2 (1-4)  1 (0-3)  0 (0-2) 
         
FeNO, n(%) 90 (83)  42 (88)  98 (85) 
     Parts per billion 33 (13-54)  17 (8-31)  13 (7-20) 
         
Spirometry, n(%) 102 (94)  46 (96)  112 (97) 
     FEV1, z-scores -0.5 (-1.3-0.1)  -0.1 (-1.0-0.5)  0.1 (-0.6-0.9) 
     FEV1/FVC 82 (77-88)  89 (83-92)  89 (86-95) 
     FEF50, z-score -0.7 (-1.4-0.1)  0.1 (-0.7-0.9)  0.2 (-0.2-0.9) 
         
Bodyplethysmography, n(%) 80 (74)  36 (75)  88 (77) 
     sReff, kPa∙s2 1.0 (0.7-1.3)  0.8 (0.7-0.9)  0.8 (0.6-0.9) 
     sRtot, kPa∙s3 1.3 (1.1-2.3)  1.4 (1.3-1.5)  1.0 (1.0-1.2) 
     RV/TLC 28 (24-33)  29 (25-37)  30 (24-34) 
         
Bronchodilator reversibility, n(%) 85 (79)  30 (63)  66 (57) 
     Increase in FEV1 in %  13 (6-25)  5 (2-19)  7 (2-28) 
1Defined as wheal size ≥3mm for mites, cat, grass, birch, mugwort and alternaria skin prick test and as ≥0.35kU/L for 
specific IgE test 
2 Reported by 4 centres 
3 Reported by 2 centres 
  
 























Clinical tests           
Allergy test1          0.71 
     ≥1 positive test* 118 39 29 47 80 (73-86) 55 (44-65) 75 (68-82) 62 (50-73) 0.35  
     ≥2 positive tests 90 26 57 60 61 (53-69) 70 (59-79) 78 (69-85) 51 (42-61) 0.31  
FeNO          0.71 
     ≥20ppb 75 25 57 73 57 (48-65) 74 (65-83) 75 (65-83) 56 (47-65) 0.31  
     ≥21ppb 72 23 60 75 55 (46-63) 77 (67-85) 76 (66-84) 56 (47-64) 0.31  
     ≥23ppb 69 17 63 81 52 (43-51) 83 (74-90) 80 (70-88) 56 (48-64) 0.35  
     ≥25ppb 66 15 66 83 50 (41-59) 85 (76-91) 81 (71-89) 56 (47-64) 0.35  
     ≥28ppb* 62 11 70 87 47 (38-56) 89 (81-94) 85 (75-92) 55 (47-63) 0.36  
Spirometry           
  FEV1          0.65 
     ≤-0.2 z-score 83 44 65 68 56 (48-64) 61 (51-70) 65 (56-74) 51 (42-60) 0.17  
     ≤-0.7 z-score* 60 23 88 89 41 (33-49) 79 (71-87) 72 (61-82) 50 (43-58) 0.20  
     ≤-1.0 z-score 42 17 106 95 28 (21-36) 85 (77-91) 71 (58-82) 47 (40-54) 0.13  
  FEV1/FVC          0.69 
     <80% 47 6 100 99 32 (25-40) 94 (88-98) 87 (77-96) 50 (43-57) 0.26  
     <86%* 88 26 59 79 60 (51-68) 75 (66-83) 77 (68-85) 57 (49-66) 0.35  
     <90% 109 58 38 47 74 (66-81) 45 (35-56) 65 (58-72) 55 (44-66) 0.19  
FEF50          0.70 
     ≤-0.3 z-score* 70 18 61 77 53 (45-62) 81 (72-88) 80 (70-87) 56 (47-64) 0.34  
     ≤-1.0 z-score 40 5 91 90 31 (23-39) 95 (88-98) 89 (76-96) 50 (42-57) 0.25  
Bodyplethysm.           
  sReff          0.62 
     ≥0.9 kPa∙s* 47 20 54 55 47 (37-57) 73 (62-83) 70 (58-81) 50 (41-60) 0.20  
     ≥1.0 kPa∙s 37 15 64 60 37 (27-47) 80 (69-88) 71 (57-83) 48 (39-58) 0.17  
  sRtot          0.77 
     ≥1.0 kPa∙s 13 7 2 6 87 (60-98) 46 (19-75) 65 (41-85) 75 (35-97) 0.33  
     ≥1.5 kPa∙s * 13 4 2 9 87 (60-98) 69 (39-91) 76 (50-93) 82 (48-98) 0.56  
  RV/TLC          0.51 
     ≥35%* 25 17 88 69 22 (15-31) 80 (70-88) 60 (43-74) 44 (36-52) 0.02  
Bronchodilator rev.           
  FEV1          0.56 
     ≥7% increase* 75 32 40 34 65 (56-74) 52 (39-64) 70 (60-79) 46 (34-58) 0.17  
     ≥10% increase 66 27 49 39 57 (48-67) 59 (46-71) 71 (61-80) 44 (34-55) 0.16  
     ≥12% increase 59 25 56 41 51 (42-61) 62 (49-74) 70 (59-80) 42 (32-53) 0.13  
Bronchodilator rev. if 
FEV1/FVC <80%
4 
         0.87 
     ≥7% increase 37 1 8 4 82 (68-92) 80 (28-99) 97 (86-99) 33 (10-65) 0.62  
     ≥10% increase* 30 0 15 5 67 (51-80) 99 (48-99) 99 (88-99) 25 (9-49) 0.67  
     ≥12% increase 26 0 19 5 58 (42-72) 99 (48-99) 99 (87-99) 21 (7-42) 0.58  
A+T+: children with asthma diagnosis and positive test result, A-T+: children without asthma diagnosis but positive test 
result, A+T-: children with asthma diagnosis but negative test result, A-T-: children without asthma and negative test 
result, Sens: sensitivity, Spec: specificity, PPV: positive predictive value, NPV: negative predictive value, YI : Youden’s-Index: 
Sensitivity + Specificity -1, AUC: area under the curve, FeNO: fractional exhaled nitric oxide, ppb: parts per billion, FEV1: 
forced expiratory volume in 1 second, FVC: forced vital capacity, FEF50: forced expiratory flow at 50% of FVC, sReff: 
specific effective airway resistance, sRtot: specific total airway resistance, RV: residual volume, TLC: total lung capacity, 
 
Bronchodilator rev.: bronchodilator reversibility 
Displayed cut-offs chosen based on proposed cut-offs from previous publications 
*Cut-off with maximum combined sensitivity and specificity (highest Youden’s-Index) 
1 Number allergens for which the skin prick test is positive: wheal size ≥3 or the specific IgE test was positive: ≥0.35 kU/l.  
2 Reported by 4 centres 
3 Reported by 2 centres 




Figure S2 Diagnostic accuracy of the diagnostic algorithm proposed by the NICE guideline 
Numbers in black: number of patients at this step. Numbers in red: number of patients with doctor diagnosed asthma at this step. Algorithm +: diagnose asthma or 
suspect asthma. Algorithm - : refer for specialist assessment or consider alternative diagnosis. FEV1: forced expiratory volume in 1 second. FVC: forced vital 
capacity. BDR: bronchodilator reversibility. FeNO: fractional exhaled nitric oxide. PEF: peak expiratory flow. 
*362 patients would need 2 weeks PEF monitoring. 
 
 
 
